MONTREAL, Feb. 4, 2021 /CNW/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or "Lumiera
"), is pleased to announce the appointment of Carlos Ponce, a successful entrepreneur,
innovator and brand builder in the natural health and wellness
industry, as its Chief Executive Officer.
After successfully closing the acquisition and setting the
foundation of Lumiera by integrating Lumiera Health Innovation Inc.
and Holizen Laboratories Inc., a subsidiary of Lumiera,
Kevin Roland has stepped down from
his role as CEO and Director.
"On behalf of the Board of Directors, we would like to thank
Kevin Roland for all his
contributions, and we greatly appreciate his offer to support
the business through the transition. Also, I am delighted that
Carlos Ponce has accepted the
position of Chief Executive Officer. Carlos is a brand builder that
will accelerate Lumiera's growth by increasing distribution and
improving consumer experiences instore and online. With his
strong leadership skills and experience in improving consumer
experiences, and operations, he brings skills that will benefit our
team, partners, customers, and consumers" said Kevin Cole, Chairman of the Board of
Lumiera.
"I am thrilled to be joining the Lumiera team, and I look
forward to building the brands and business to create value for our
shareholders. With the recent launch of
BazzzicsTM, a natural sleep aid product, plus the
incredible innovation pipeline, Lumiera Health is well positioned
for a strong growth," said Carlos
Ponce.
About Mr. Carlos Ponce
A proven team, brand and business builder that understands
pre-scale businesses and the steps to accelerate growth including
operations and raising capital. Over his 20+ year career, he
has leveraged his strategic and operational skills to build
businesses across multiple categories; most recently as CEO of
Biolux Natural Health, and previous roles including Creative and
Strategy Director at Vibrant Marketing and co-founder of Logient, a
web development agency.
About Lumiera Health Inc.
Lumiera specializes in the development and commercialization of
evidence-based botanical products for the healthcare industry. The
Company sells both oral and topical botanical agents to help manage
unmet medical needs through its Holizen Laboratories division.
Lumiera is also developing and commercializing a unique portfolio
of products acting on the endocannabinoid system and providing
innovative solutions for chronic pain and inflammation. The Company
is a pioneer in the health and pain management innovation space and
the Lumiera brand is rooted in the core brand values of science,
nature and compassion. Passionate about making people feel
better, we deliver trustworthy and scientifically proven solutions
that work with the body's own system.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year ended
November 30, 2019, which is available
under the issuer's SEDAR profile at www.sedar.com. Material
factors or assumptions were applied in providing forward-looking
information. Many factors could cause the actual results,
performance or achievements that may be expressed or implied by
such forward-looking information to vary from those described
herein should one or more of these risks or uncertainties
materialize. Should any factor affect Lumiera in an unexpected
manner, or should assumptions underlying the forward-looking
information prove incorrect, the actual results or events may
differ materially from the results or events predicted. Any such
forward-looking information is expressly qualified in its entirety
by this cautionary statement. Moreover, Lumiera does not assume
responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Mondias Natural Products Inc.